Protalix BioTherapeutics (PLX)
Develops and manufactures plant-cell-derived enzyme therapies for rare diseases.
$2.80
vs last close−0.04 (−1.41%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 18.18% | 14.65M shares | |
|---|---|---|---|
| 109 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 81.82% | 65.92M shares | |
| remainder | |||
80.57M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
109 holders · 14.65M shares · 20 new positions · 60 increased · 16 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 4.05M | 5.02% | +429.7K | Aug 7, 2026 |
| Renaissance Technologies LLC | 1.10M | 1.36% | −128.8K | Aug 13, 2026 |
| State Street Corp | 983.6K | 1.22% | +10.8K | Aug 7, 2026 |
| Geode Capital Management, LLC | 980.0K | 1.22% | +114.7K | Aug 12, 2026 |
| Northern Trust Corp | 922.3K | 1.14% | +36.9K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 510.6K | 0.63% | +78.2K | Aug 13, 2026 |
| Stratos Wealth Partners, Ltd. | 500.0K | 0.62% | 0 | Aug 11, 2026 |
| Dimensional Fund Advisors LP | 493.4K | 0.61% | +196.6K | Aug 11, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.02% | 4.05M | 13G | Jul 29, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.